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Abstract
Background: The sun-dried rind of the immature fruit of pomegranate (Punica granatum) is presently used as a herbal 
formulation (OMARIA, Orissa Malaria Research Indigenous Attempt) in Orissa, India, for the therapy and prophylaxis of 
malaria. The pathogenesis of cerebral malaria, a complication of the infection by Plasmodium falciparum, is an 
inflammatory cytokine-driven disease associated to an up-regulation and activity of metalloproteinase-9 and to the 
increase of TNF production. The in vitro anti-plasmodial activity of Punica granatum (Pg) was recently described. The aim 
of the present study was to explore whether the anti-malarial effect of OMARIA could also be sustained via other 
mechanisms among those associated to the host immune response.
Methods: From the methanolic extract of the fruit rind, a fraction enriched in tannins (Pg-FET) was prepared. MMP-9 
secretion and expression were evaluated in THP-1 cells stimulated with haemozoin or TNF. The assays were conducted 
in the presence of the Pg-FET and its chemical constituents ellagic acid and punicalagin. The effect of urolithins, the 
ellagitannin metabolites formed by human intestinal microflora, was also investigated.
Results: Pg-FET and its constituents inhibited the secretion of MMP-9 induced by haemozoin or TNF. The effect 
occurred at transcriptional level since MMP-9 mRNA levels were lower in the presence of the tested compounds. 
Urolithins as well inhibited MMP-9 secretion and expression. Pg-FET and pure compounds also inhibited MMP-9 
promoter activity and NF-kB-driven transcription.
Conclusions: The beneficial effect of the fruit rind of Punica granatum for the treatment of malarial disease may be 
attributed to the anti-parasitic activity and the inhibition of the pro-inflammatory mechanisms involved in the onset of 
cerebral malaria.
Background
Pomegranate (Punica granatum L., Punicaceae) is used in
the traditional medicine of different Asian cultures for
the treatment of a variety of ailments. In Ayurvedic medi-
cine, the plant, described under its Sanskrit name "dal-
ima" (fruit), is considered as a "blood tonic" and used to
cure parasitic infections [1]. The decoction of the root
was found beneficial in fevers and chronic debility due to
malaria. Moreover, the fruit rind powder was found to
possess immunomodulatory properties [2].
The eastern province of Orissa (India) is an area
endemic for both Plasmodium falciparum and Plasmo-
dium vivax; malaria constitutes a major health problem
for the population, in particular for those living in rural
areas. Since 1998, malaria patients referring to the
Ayurveda dispensary receive a herbal preparation named
OMARIA, made of sun-dried rind of the immature P. gra-
natum  fruits (Pg). OMARIA (the acronym for Orissa
Malaria Research Indigenous Attempt) is distributed as a
home based economic remedy for prophylaxis under the
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banner "Fight Malaria At Home/Ghare Maro Malaria.
Clinical application started in 1998 by the Indian Red
Cross Society Charitable Ayurveda dispensary (c/o Dis-
trict Magistrate Koraput) on behalf of D. Bhattacharya.
Dispensary records indicate that OMARIA can success-
fully control P. falciparum and P. vivax infections in all
patients including infants and pregnant women [3,4].
OMARIA is administered as gelatine capsules (courtesy
of m/s Sunil Health Care Ltd. New Delhi, India), contain-
ing each 825-850 mg of Pg. The therapeutic dose is one
capsule every eight hours for three consecutive days. For
prophylaxis, one capsule has to be taken in every day
(children receive half the dosages) for a period ranging
between two or four weeks/six months. Records from the
Ayurveda-Indian Red Cross Society indicate a positive
impact on the health status of the population under
OMARIA coverage: the prophylactic intervention
appears not only to reduce malaria episodes, but also the
incidence of other infectious diseases, such as measles,
chicken pox and conjunctivitis [4].
The reported anti-malarial effectiveness of the OMA-
RIA was attributed to the anti-parasitic activity of a frac-
tion enriched in tannins (Pg-FET) obtained from the Pg
methanolic extract [5]. The effect could be attributed to
different constituents of Pg-FET, namely ellagic acid (EA),
and punicalagin, which inhibited in vitro the growth of Pf
asexual blood stages [5,6]. Whether Pg preparations could
help to control the malarial disease by adjuvant mecha-
nisms, as well, remains unexplored. The present research
was undertaken with the aim of testing the effects of Pg
preparations on the pathways involved in the onset severe
malaria, which may develops during Pf infection.
It is largely accepted that severe malaria is an inflam-
matory cytokine-driven disease. There is remarkable evi-
dence that tumour necrosis factor (TNF) and interleukin-
1 are important contributors to the systemic disease
caused by the infectious agent Pf [7,8].
The innate immune system seeks to destroy the proto-
zoa and remove the remnants via phagocytosis by mono-
cytes and neutrophils. Circulating levels of TNF, a
mediator of the innate immune system, are increased
after infection, as a consequence of stimulation of mono-
cyte-macrophages by infected red blood cells (IRBC) or
phagocytosis of haemozoin (Hz, the malarial pigment)
phagocytosis by human monocytes [9-12]. TNF in turn
enhances the synthesis of metalloproteinase-9 (MMP-9)
in monocytes and macrophages [9,10]. More recently, it
has been shown that human monocytes fed with Hz or
IRBC display increased MMP-9 activity and protein/
mRNA expression and increased production of TNF and
a role of MMP-9 and TNF in the onset of cerebral malaria
has been postulated [11,12].
The wide-range of therapeutic benefits of pomegranate
have been attributed to its anti-oxidant and anti-inflam-
matory properties. It was shown that Pg fruit juice and its
constituents ellagitannins, have a significant and broad
inhibitory effect on MMPs, including MMP-9 [13,14,1].
In addition, Pg  fruit juice and ellagitannins suppress
inflammatory cell signalling induced by TNF in colon
cancer cells [15].
However, it was not clear which of the compounds
present in Pg-FET or ellagitannins could antagonize the
host inflammatory response. In the present study, it has
been investigated whether Pg-FET, EA, and punicalagin,
the compounds previously identified in Pg-FET, inhibited
MMP-9 upregulation and secretion in THP-1 cells
induced by native haemozoin (Hz) and TNF. Since ellagi-
tannins were shown to be converted by the human gut
microflora into urolithin A, B and urolithin-8-methyle-
ther [16-20] these metabolites were also evaluated for
their inhibitory effect.
Here, it is shown that Pg-FET and its constituents EA
and punicalagin, all inhibited the MMP-9 secretion and
expression in THP-1 cells, fed with Hz or TNF . Pg-FET
and individual compounds were also able to inhibit
MMP-9 promoter activity after stimulation with Hz. The
inhibitory effect was partially due to the inhibition of NF-
κB pathway. Urolithins were also active. It is then plausi-
ble that Pg, in addition to the direct effect on the parasite,
modulates the malarial disease via the inhibition of the
inflammatory response induced by haemozoin.
Methods
Chemicals
Amberlite XAD16 resin was purchased from Sigma-
Aldrich (Milan-Italy) and Kollidon® from BASF Chemical
Company (Germany). Ellagic acid (EA) was acquired
from Fluka-Sigma-Aldrich (Milan, Italy), punicalagin was
obtained from AvaChem Scientific LLC, San Antonio,
Texas, USA. Urolithin A, B and urolithin A-8-methyle-
ther were synthesized as described [5]. All reagents were
purchased from Fluka-Sigma-Aldrich (Milan, Italy).
Plant material and extract fractionation
The pomegranate immature fruit was manually plucked
from plants growing in tropical forest area of India. The
fruits were cut and the arils discarded. The rind was sun-
dried, finely ground, delipidized by petroleum ether
(40:60) and extracted twice with methanol (MeOH, 1 g/
10 ml). The w/w yield of the MeOH extract was 38% with
respect to the starting crude material. For the tannin
removal, the extract was treated with Kollidon® (1:25, w/
w) thus obtaining Pg-MeOH-DT.
For the preparation of a fraction enriched in tannins
(Pg-FET), 5 g of the Pg-MeOH extract were dissolved in
500 ml of water and chromatographed on Amberlite
XAD16 resin as described [5]. The w/w yield of Pg-FETDell'Agli et al. Malaria Journal 2010, 9:208
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was 60% with respect to the Pg-MeOH extract. Pg-FET
was analyzed by HPLC-MS as described [5].
Purification of native haemozoin
Plasmodium falciparum cultures were carried out
according to the method of Trager and Jensen with slight
modifications [21]. Briefly, a chloroquine (CQ)-sensitive
P. falciparum strain (D10) was maintained at 5% haemat-
ocrit at 37°C in complete culture medium (RPMI 1640
supplemented with NaHCO3 24 mM, 1% AlbuMax II,
0.01% hypoxanthine, 20 mM HEPES, and 2 mM glu-
tamine). All cultures were maintained in a standard gas
mixture, consisting of 1% O2, 5% CO2, 94% N2.
T o separate haemozoin, cells were washed twice with
serum-free culture medium, resuspended to 25% haemat-
ocrit, and fractionated onto a discontinuous Percoll/4%
sorbitol (w/v) gradient (0, 40, 80%). After centrifugation
at 1075 g, native haemozoin was collected from the top of
the gradient, 0-40% interphase. Native haemozoin was
washed three times with PBS and stored at 20% (v/v) in
PBS at -20°C. The haem content of HZ was determined
by building a standard curve with increasing concentra-
tions of haemin (0-100 μM) and measuring absorbance at
405 nm of a weighed amount of the compound dissolved
in 0.1 M NaOH.
Cell cultures
Human THP-1 monocytic leukaemia cells (ATCC, Ted-
dington, UK) were grown in RPMI 1640 (Invitrogen s.r.l.,
Milano, Italy) supplemented with 100 units penicillin/ml,
100 μg streptomycin/ml, 10 mM HEPES, 1 mM Sodium
Pyruvate, 0.05 mM beta-mercaptoethanol, and 10% heat-
inactivated foetal calf serum (FCS, Euroclone, Milano,
Italy).
Pg-FET was used at 50-100 μg/ml. Concentrations were
chosen by taking into consideration the daily dosage of
P.g. (2550 mg/die), the recovery of the MeOH extract, the
percentage of FET in the MeOH extract and assuming
complete absorption.
Pg- F E T  a n d  p u r e  c o m p o u n d s  w e r e  u s e d  a t  n o  t o x i c
concentrations. Cytotoxicity was evaluated by testing
alterations of mitochondrial functionality as assessed by
MTT test [22]. No sign of cytotoxicity was observed at
concentrations ranging from 50 to 250 μg/ml for FET and
25 μM for individual compounds.
To evaluate the effect of Pg-MeOH extract on the
MMP-9 secretion in PMA-treated THP-1, 1.2 × 106 cells/
ml were plated in 24-well plates in the presence of 10 nM
PMA to induce differentiation to macrophages. After 48
hours, cells were treated with the extract for 24 hours by
using RPMI 1640 deprived of FCS, and the medium col-
lected and subject to zymography.
To evaluate the effect of the fraction/compounds on
TNF-induced MMP-9 secretion, THP-1 cells were plated
in 96-well plated (1 × 106 cells/ml) in the presence of 10
ng/ml TNF, and treated with the compounds under study
or the only vehicle (final concentration 0.1%) by using
medium deprived of FCS. 48 hours after, cells were cen-
trifuged and the media collected for zymography.
To evaluate the effect on HZ-induced MMP-9 secre-
tion, THP-1 cells were plated in 96-well plates (1 × 106
cells/ml) in the presence of 6 μg/ml HZ and incubated at
37°C for four hours. Cells were centrifuged and resus-
pended in RPMI 1640 without FCS in the presence of the
compounds under study or the vehicle. 48 hours after,
cells were centrifuged and used for RNA extraction and
protein measurement, whereas the media were subject to
zymography.
SDS-PAGE zymography
The gelatinolytic activity of MMP-9 secreted by THP-1
cells was evaluated as previously described [23]. Briefly,
cells were exposed to TNF or HZ in the presence of the
tested compounds. Epigallocatechin-3-gallate (EGCg) 20
μM was used as reference inhibitor of MMP-9 expression
[23]. Control samples received the vehicle only. Aliquots
of conditioned medium underwent electrophoresis on
7.5% polyacrylamide gels containing 10% SDS and gelatin
(1 mg/ml). The gels were then washed in 2.5% Triton X-
100 (Sigma-Aldrich, Milan, Italy) at room temperature
and then incubated overnight at 37°C (50 mM Tris pH 7.5
containing 150 mM NaCl, 10 mM CaCl2, 1 μM ZnCl2;
activation buffer). At the end of the incubation, the gels
were stained with Coomassie brilliant blue R-250 (Sigma-
Aldirch, Milan, Italy). For the quantification of zymo-
grams, densitometric scanning was performed using
QuantityOne software (Bio-Rad) and each lysis area was
normalized against intracellular protein content deter-
mined by Bradford assay [24].
Real time RT-PCR
THP-1 cells were treated as described above. Total RNA
was extracted with the RNeasy Mini Kit (Qiagen, S.p.A.,
Milan, Italy) according to the manufacturer's instruc-
tions. Total RNA was quantified using the Ribo Green
RNA Quantitation Assay from Molecular Probes (Invit-
rogen, Milan, Italy). Aliquots corresponding to 1000 ng of
total RNA were reverse transcribed by using the
iScript™cDNA synthesis kit (Bio-Rad Laboratories, Milan,
Italy) following the manufacturer's protocol. Aliquots of
the cDNA were subject to real-time PCR with a SYBR
Green kit (Bio-Rad Laboratories, Milan, Italy) following
the manufacturer's instructions. 18 S rRNA was used as
the housekeeping gene for sample normalization and was
amplified in separate wells within the same plate. Primers
for real-time PCRs were designed with Primer Express
software (Applied Biosystems, Monza, Italy) and opti-
mized to work in a two-step protocol. The oligonucle-Dell'Agli et al. Malaria Journal 2010, 9:208
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otides were synthetized by Primm (Milan, Italy) and the
sequences are the following: MMP-9, forward primer
5'AAACCGAGTTGGAACCACGA3', reverse primer 5'T
CAGGGAGACGCCCATTTC3'; 18 S rRNA forward
primer 5'CGGCTACCACATCCAAGGAA3', reverse
primer 5'AGGTAGTGACGAAAAATAACAATCACGG
3'. The specificity of the amplified products was moni-
tored performing melting curves at the end of each
amplification reaction. All amplicons generated a single
peak, thus reflecting the specificity of the primers. Dex-
amethasone was used as a reference inhibitor of MMP-9
expression (~80% inhibition at 100 nM).
Plasmid construction
The DNA fragment corresponding to 1024 bp of the 5'-
flanking region of the human MMP-9 promoter region (-
1005 to + 19) cloned into the PGL3-basic vector and the
corresponding mutant construction in the κB site
(GGAATTCCCC to GtcAacagCC) [25] were a kind gift of
Dr. Siro Simizu (Antibiotics Laboratory and Chemical
Biology Department, Saitama University, Japan). pNF-
κB-luc containing the luciferase gene under the control of
three κB responsive elements of the promoter of the E-
selectin gene was a kind gift of N. Marx (Department of
Internal Medicine II-Cardiology, Ulm, Germany).
Assay of NF-κB and MMP-9 promoter activity
The NF-κB and MMP-9 promoter activities were evalu-
ated in 96-wells plates by means of transient transfection
assays in THP-1 cells by using the DEAE-dextran method
as previously described [26]. Briefly, cells were exposed to
a mixture of DNA-dextran (750 μg/ml final concentra-
tion) for 30 min at 37°C, using 700 ng/ml NF-κB-luc and
500 ng/ml MMP-9-luc or mutated mκB-luc reporter plas-
mid/1.5 × 105 cells. Cells were then incubated in FCS-
supplemented RPMI 1640 (final volume, 100 μl/well). 48
hours after cells were stimulated with HZ (6 μg/ml) for
four hours and treated with the fraction/compounds
under study, as described for MMP-9 secretion. 48 hours
after, 100 μl/well Britelite plus (Perkin Elmer Waltham,
MA, USA) was added and the plate read at the luminom-
eter Victor™X3 Perkin Elmer 2030 (Perkin Elmer
Waltham, MA, USA). Parthenolide (10 μM) was used as
reference inhibitor of the NF-κB (~50% inhibition) and
MMP-9 (~80% inhibition) promoter activity. Data are
expressed as mean ± S.D. of triplicate samples.
Statistical analysis
All experiments were reproduced at least three times and,
where indicated, representative experiments are shown.
Statistical analyses were performed with GraphPad Prism
5 software, using 1-way ANOVA test followed by Bonfer-
roni's post hoc test. The significance was indicated as fol-
lows: * p < 0.05; ** p < 0.01; *** p < 0.001.
Results
Effect of Pg-FET on MMP-9 secretion and gene expression
In a preliminary experiment conducted in PMA-differen-
tiated THP-1 cells, Pg-MeOH extract at 50 μg/ml inhib-
ited the secretion of MMP-9 by 61%. When the extract
was deprived of tannins, the inhibitory effect was dra-
matically reduced (-20%, not statistically significant vs
controls). This result indicated that tannins were likely to
be the active principles. Therefore a fraction enriched in
tannins (Pg-FET) was prepared as described in the meth-
odology section. To test Pg-FET and individual com-
pounds, undifferentiated THP-1 cells were stimulated
with Hz or TNF . The concentration of HZ used in the
experiments (6 μg/ml) reflects the levels of Hz likely to be
present in the plasma of infected patients [27]. Hz
induced a significant increase of the MMP-9 mRNA lev-
els and the amount of protein secreted by THP-1 cells
compared to controls (Figure 1). Pg-FET, at 50 and 100
μg/ml, antagonized the increase of Hz-induced MMP-9
secretion by 78% and 95%, respectively, and the mRNA
levels of 92% and 97%, respectively (Figure 1). Similarly,
in cells stimulated by TNF, Pg-FET antagonized the
increase of MMP-9 secretion by TNF, but the effect was
significant only at the concentration of 100 μg/ml (-62%).
As shown in Figure 2, Hz also induced a 2.5 fold increase
of MMP-9 promoter activity, which was completely
antagonized (80 and 90% inhibition) by Pg-FET at 50 and
100 μg/ml, respectively, thus confirming that the down-
regulation of MMP-9 secretion was consequent to a
decreased rate of MMP-9 gene transcription.
Effect of punicalagin, EA and urolithins on MMP-9 secretion 
and gene expression
As previously reported, EA and punicalagin represent the
13.4% and 29.1% of Pg-FET, respectively [5]. Punicalagin
at 1 and 10 μM inhibited the release of MMP-9 in Hz
stimulated THP-1 cells by 38% and 79%; the MMP-9
mRNA levels decreased accordingly (-47% at 10 μM; Fig-
ure 3A-B). EA at 1 and 10 μM inhibited the release of
MMP-9 in Hz-stimulated THP-1 cells by 52 and 66%,
respectively, and the MMP-9 expression by 56 and 65%,
respectively (Figure 3C-D). Ellagitannins were also able to
affect MMP-9 transcription since EA inhibited Hz-
induced promoter activity by 38% and 50% at 1 and 10
μM, respectively, while the inhibitory effect of puni-
calagin was only statistically significant at 10 μM (-65%)
(Figure 4).
Urolithins A, B and 8ME at 25 μM inhibited the release
of MMP-9 in either Hz or TNF stimulated THP-1 cells,
urolithins A and B being the most active (-87, -37, and -
74%, respectively; Figure 5A); the effect was associated to
a decrease of MMP-9 mRNA levels (-88%, -95% and -82%
respectively; Figure 5B). Similarly urolithins A, B and 8-Dell'Agli et al. Malaria Journal 2010, 9:208
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ME decreased the secretion of MMP-9 in cells stimulated
with TNF (-58, -60 and -44%, respectively; Figure 6).
Effect of Pg-FET and individual compounds on the NF-κB 
system
To evaluate if Pg-FET and individual components inhib-
ited MMP-9 secretion and gene expression by acting on
the NF-κB system, THP-1 cells were transiently trans-
fected with a reported plasmid bearing the luciferase
gene under the control of a promoter containing NF-κB
binding sites. Transfected cell were then stimulated with
Hz or TNF. As shown in Figure 7A, Pg-FET, at 50 and 100
μg/ml, inhibited the Hz-induced NF-κB promoter activity
by 28% and 50%, respectively. Both individual compounds
at 1-10 μM antagonized the Hz-induced promoter activ-
ity: -30% and - 41% for EA; -32% and -45% for puni-
calagin, respectively (Figure 7B). To further confirm that
the inhibition of MMP-9 promoter activity reflected a
down-regulation of the NF-kB system, Pg-FET, EA, and
punicalagin were tested on THP-1 cells transfected with
MMP-9 promoter mutated at the kB binding site (mκB).
As reported in Figure 8A, the mutated promoter activity
was resistant to Hz induction in comparison to the wild-
type (1.3 fold vs 2.5 fold increase) and the inhibitory
effect by Pg-FET was less pronounced as well (-20% and -
35% at 50 and 100 μg/ml, respectively). Consistently with
Figure 1 Effect of Pg-FET on MMP-9 secretion (panel A) and 
mRNA levels (panel B) in THP-1 cells stimulated with Hz. Pg-FET 
(50-100 μg/ml) antagonized the increase of Hz-induced MMP-9 secre-
tion by 78% and 95%, respectively (Panel A), and the mRNA levels of 
92% and 97%, respectively (Panel B). All experiments were reproduced 
at least three times. Statistical analyses were performed with GraphPad 
Prism 5 software, using 1-way ANOVA test followed by Bonferroni's 
post hoc test. The significance was indicated as *** p < 0.001.
Figure 2 Effect of Pg-FET on Hz-induced MMP-9 promoter activi-
ty. Hz also induced a 2.5 fold increase of MMP-9 promoter activity, 
which was completely antagonized (80 and 90% inhibition) by Pg-FET 
at 50 and 100 μg/ml, respectively. Parthenolide (10 μM) was used as 
reference inhibitor of MMP-9 (~80% inhibition) promoter activity. Data 
are expressed as mean ± S.D. of triplicate samples. All experiments 
were reproduced at least three times. Statistical analyses were per-
formed with GraphPad Prism 5 software, using 1-way ANOVA test fol-
lowed by Bonferroni's post hoc test. The significance was indicated as 
*** p < 0.001.
Figure 3 Effect of punicalagin and EA on MMP-9 secretion (panel 
A, C) and mRNA levels (B, D) in THP-1 cells stimulated with Hz. Pu-
nicalagin at 1 and 10 μM inhibited the release of MMP-9 in Hz stimulat-
ed THP-1 cells by 38% and 79%; the MMP-9 mRNA levels decreased 
accordingly (-47% at 10 μM; Figure 3A-B). EA at 1 and 10 μM inhibited 
the release of MMP-9 in Hz-stimulated THP-1 cells by 52 and 66%, re-
spectively, and the MMP-9 expression by 56 and 65%, respectively (Fig-
ure 3C-D). All experiments were reproduced at least three times. 
Statistical analyses were performed with GraphPad Prism 5 software, 
using 1-way ANOVA test followed by Bonferroni's post hoc test. The 
significance was indicated as follows: ** p < 0.01; *** p < 0.001.Dell'Agli et al. Malaria Journal 2010, 9:208
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these results, punicalagin at 10 μM inhibited the mutated
promoter activity by only 25%, and EA was inactive (Fig-
ure 8B).
Discussion
The sun-dried rind of the immature fruit of Punica gra-
natum  is used as an herbal anti-malarial remedy. The
drug is rich in ellagitannins, namely EA, punicalagin,
punicalin and EA glycosides [5]. In a previous work we
demonstrated that the fraction enriched in tannins (Pg-
FET) obtained from the methanolic extract of Pg inhib-
ited in vitro the growth of P. falciparum asexual blood
stages. According to previous results and those from
other groups, ellagitannins and in particular EA, were
identified as the active principles [5,6,28,29]
A phytocomplex, such as a herbal formulation, is char-
acterized by a mixture of chemicals with a wide array of
biological effects. The overall clinical effects of a phyto-
complex represent a synthesis of several different activi-
ties exerted by clusters of molecules acting on different
molecular targets. Therefore, it was expected that the
anti-malarial activity of Pg  could be attributed to the
action of the components of the phytocomplex on other
factors involved in the pathogenesis of the malarial dis-
ease and not only on the parasite itself. With this in mind,
the possibility that Pg-FET could interact with the pro-
duction of MMP-9, an enzyme directly implicated in the
pathogenesis of malaria was considered. MMP-9 expres-
sion is higher in mice brain with cerebral malaria [30] and
human monocytes fed with Hz or trophozoite-parasit-
ized red blood cells displayed increased activity and pro-
tein/mRNA expression of MMP-9 and increased
production of TNF [11,12]. The enhancement of MMP-9
activity was causally related to the increase of IL-1 beta
production. 15-HETE, one of the monohydroxy deriva-
tives of polyunsaturated fatty acids (OH-PUFAs) attached
to Hz, was considered responsible for the increase of IL1-
beta production and MMP-9 activity [12].
The present data confirm that Hz or TNF increase the
secretion and mRNA levels of MMP-9 in THP-1/mono-
cytes. In addition, it has been shown that Pg-FET and
individual compounds are able to antagonize such stimu-
lation. The total fraction and the pure compounds inhib-
ited Hz and TNF-induced MMP-9 promoter activity.
Considering that the level of EA and punicalagin mea-
sured in Pg-FET is 13.4 and 29.1%, the amount of Pg-FET
necessary to exert this effect is compatible with the con-
Figure 4 Individual compounds EA and punicalagin inhibit Hz-in-
duced MMP-9 promoter activity. Ellagitannins were able to affect 
MMP-9 transcription since EA inhibited Hz-induced promoter activity 
by 38% and 50% at 1 and 10 μM, respectively, while the inhibitory ef-
fect of punicalagin was only statistically significant at 10 μM (-65%). 
Parthenolide (10 μM) was used as reference inhibitor of the MMP-9 
(~80% inhibition) promoter activity. Data are expressed as mean ± S.D. 
of triplicate samples. All experiments were reproduced at least three 
times and, where indicated, representative experiments are shown. 
Statistical analyses were performed with GraphPad Prism 5 software, 
using 1-way ANOVA test followed by Bonferroni's post hoc test. The 
significance was indicated as ** p < 0.01.
Figure 5 Effect of urolithins on MMP-9 secretion (panel A) and 
mRNA levels (panel B) in THP-1 cells stimulated with Hz. Urolithins 
A, B and 8ME at 25 μM inhibited the release of MMP-9 in Hz-stimulated 
THP-1 cells, urolithins A and B being the most active (-87, -37, and -74%, 
respectively; Panel A); the effect was associated to a decrease of MMP-
9 mRNA levels (-88%, -95% and -82% respectively; Panel B). All experi-
ments were reproduced at least three times. Statistical analyses were 
performed with GraphPad Prism 5 software, using 1-way ANOVA test 
followed by Bonferroni's post hoc test. The significance was indicated 
as follows: ** p < 0.01; *** p < 0.001.Dell'Agli et al. Malaria Journal 2010, 9:208
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centrations of EA and punicalagin necessary for the inhi-
bition of MMP-9. It can then be concluded that EA and
punicalagin greatly contribute to the overall effect
exerted by Pg-FET.
These two compounds are metabolized in vivo by the
human intestinal microflora into at least three metabo-
lites named urolithins [16-20]. It has been reported here
that urolithins as well diminished MMP-9 secretion and
mRNA levels induced by HZ or TNF. The effect could be
observed at concentrations of metabolites (25 μM) close
to those attained in plasma (18-20 μM) after pomegran-
ate juice consumption [16]. These results suggest that
also the metabolites of ellagitannins participate to the
control of excessive production of MMP-9 and in turn
they may protect against the increased production and
function of the noxious cytokine TNF.
To investigate more deeply how Pg-ellagitannins affect
the signalling cascade leading to MMP-9 expression, the
involvement of NF-κB system was investigated. It is
known that several cytokines, including TNF, act at dif-
ferent levels ultimately promote the binding of the NF-κB
complex to target sequences thus inducing the transcrip-
tion of several genes, among which the MMP-9 gene. As
in many other situations, in Hz-fed murine macrophages,
TNF up-regulation is linked to the activation of the NF-
κB pathway [31,32]. As already shown by Prato et al in
human monocytes [12], Hz increased TNF levels in THP-
1 cells [33]. By showing that Pg-FET and its ellagitannins
inhibited NF-κB promoter activity and that the effect was
evident only when the wild type promoter was used and
less pronounced when the promoter was mutated for the
NF-κB binding site, it has been demonstrated that Pg-
FET and ellagitannins block NF-κB-driven transcription
thus affecting the entire cytokine cascade. However, it
could be predicted that their anti-inflammatory role goes
beyond the effects on MMP-9.
In addition, ellagitannins and their hydrolysis products,
i.e. EA, have been shown to inhibit the activation of
inflammatory pathways including but not limited to the
NF-κB system [34-36]. Thus, additional mechanisms of
action could also be considered, such as mitogen-acti-
vated protein kinases (MAPK), which are modulated by
pomegranate [35,37,38]. The peroxidation of the lipid
components (HETEs) attached to Hz has been suggested
to be instrumental for enhanced MMP-9 activity [12]. Pg-
FET is a mixture of polyphenols with high antioxidant
Figure 6 Effect of urolithins on MMP-9 secretion and mRNA levels 
in THP-1 cells stimulated with TNF. Urolithins A, B and 8-ME at 25 μM 
decreased the secretion of MMP-9 in cells stimulated with TNF (-58, -60 
and -44%, respectively). All experiments were reproduced at least 
three times. Statistical analyses were performed with GraphPad Prism 
5 software, using 1-way ANOVA test followed by Bonferroni's post hoc 
test. The significance was indicated as *** p < 0.001.
Figure 7 Effect of Pg-FET (panel A) and individual compounds 
(panel B) on NF-kB promoter activity in THP-1 cells stimulated 
with Hz. Pg-FET, at 50 and 100 μg/ml, inhibited the Hz-induced NF-κB 
promoter activity by 28% and 50%, respectively. Both individual com-
pounds at 1-10 μM antagonized the Hz-induced promoter activity: -
30% and - 41% for EA; -32% and -45% for punicalagin, respectively. Par-
thenolide (10 μM) was used as reference inhibitor of the NF-κB (~50% 
inhibition) promoter activity. Data are expressed as mean ± S.D. of trip-
licate samples. All experiments were reproduced at least three times 
and, where indicated, representative experiments are shown. Statisti-
cal analyses were performed with GraphPad Prism 5 software, using 1-
way ANOVA test followed by Bonferroni's post hoc test. The signifi-
cance was indicated as follows: * p < 0.05; ** p < 0.01.Dell'Agli et al. Malaria Journal 2010, 9:208
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capacity that are likely capable to prevent the non-enzy-
matic oxidation of PUFAs to hydroperoxides.
Conclusions
In conclusion, the beneficial clinical effects of the fruit
rind of Punica granatum for the treatment of malaria
possibly include the direct anti-parasitic activity and the
ability to limit the excess inflammatory response of the
host, thus limiting the risk of progression to the more
severe form of the disease, including the onset of cerebral
malaria.
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